ATE384698T1 - Therapeutische piperazin-derivate für die behandlung von schmerzen - Google Patents

Therapeutische piperazin-derivate für die behandlung von schmerzen

Info

Publication number
ATE384698T1
ATE384698T1 AT03762220T AT03762220T ATE384698T1 AT E384698 T1 ATE384698 T1 AT E384698T1 AT 03762220 T AT03762220 T AT 03762220T AT 03762220 T AT03762220 T AT 03762220T AT E384698 T1 ATE384698 T1 AT E384698T1
Authority
AT
Austria
Prior art keywords
compound
animal
effective amount
disclosed
pain
Prior art date
Application number
AT03762220T
Other languages
English (en)
Inventor
Donald Kyle
Qun Sun
Laykea Tafesse
Chongwu Zhang
Xiaoming Zhou
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE384698T1 publication Critical patent/ATE384698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03762220T 2002-06-28 2003-06-27 Therapeutische piperazin-derivate für die behandlung von schmerzen ATE384698T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39196202P 2002-06-28 2002-06-28
US41103002P 2002-09-17 2002-09-17
US41314802P 2002-09-25 2002-09-25
US41658202P 2002-10-08 2002-10-08

Publications (1)

Publication Number Publication Date
ATE384698T1 true ATE384698T1 (de) 2008-02-15

Family

ID=30003987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762220T ATE384698T1 (de) 2002-06-28 2003-06-27 Therapeutische piperazin-derivate für die behandlung von schmerzen

Country Status (20)

Country Link
US (3) US7279493B2 (de)
EP (1) EP1556354B1 (de)
JP (1) JP4621502B2 (de)
CN (1) CN100457735C (de)
AT (1) ATE384698T1 (de)
AU (1) AU2003247829A1 (de)
BR (1) BR0312322A (de)
CA (1) CA2491079C (de)
CY (1) CY1107411T1 (de)
DE (1) DE60318875T2 (de)
DK (1) DK1556354T3 (de)
EA (1) EA200500114A1 (de)
ES (1) ES2300613T3 (de)
IL (1) IL165862A0 (de)
MX (1) MXPA04012748A (de)
NO (1) NO20050371L (de)
NZ (1) NZ537292A (de)
PT (1) PT1556354E (de)
RS (1) RS114804A (de)
WO (1) WO2004002983A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
DK1556354T3 (da) 2002-06-28 2008-06-02 Euro Celtique Sa Terapeutiske piperazinderivater, der er egnede til behandling af smerter
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
PT1641775E (pt) * 2003-07-03 2009-04-23 Euro Celtique Sa Derivados de 2-piridina-alcino úteis para o tratamento da dor
PL1648878T3 (pl) * 2003-07-24 2009-10-30 Euro Celtique Sa Związki piperydynowe i zawierające je kompozycje farmaceutyczne
EP1867644B1 (de) * 2003-07-24 2009-05-20 Euro-Celtique S.A. Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
GEP20094675B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
PL1942106T3 (pl) 2003-08-01 2012-02-29 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
AP2006003678A0 (en) * 2003-12-30 2006-08-31 Euro Celtique Sa Piperazines useful for treating pain
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AU2011226773C1 (en) * 2007-04-27 2012-07-26 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
PL2142529T3 (pl) * 2007-04-27 2014-06-30 Purdue Pharma Lp Antagoniści trpv1 i ich zastosowania
US8362012B2 (en) 2008-04-18 2013-01-29 Daewoong Pharmaceutical Co., Ltd. Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
CA2788355C (en) 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Phenyl-heteroaryl derivatives and methods of use thereof
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
CN103717594B (zh) 2011-06-22 2016-12-14 普渡制药公司 包含二羟基取代基的trpv1拮抗剂及其用途
ES2673221T3 (es) * 2012-06-28 2018-06-20 Abbvie Inc. Cianoguanidinas y su uso como agentes antivirales
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN105944083A (zh) * 2016-05-03 2016-09-21 董桂芬 一种用于治疗纤维肌痛综合症的复方护理剂及其制备方法
ES3014630T3 (en) 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
CN112716979B (zh) * 2021-01-26 2022-11-04 上海优祺生物医药科技有限公司 羊膜上皮细胞条件培养基的制药用途
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI56836C (fi) * 1977-10-25 1980-04-10 Fermion Oy 4-substituerade piperazin-1-(n-aryl-n'-cyano)-karboximidamider som aer mellanprodukter vid framstaellningen av farmakologiskt vaerdefulla 6,7-dimetoxi- eller 6,7,8-trimetoxi-4-amino-2-(4-substituerade-piperazin-1-yl)-kinazoliner
US4450272A (en) * 1982-05-06 1984-05-22 American Cyanamid Company Antiatherosclerotic 1-piperazine-thicarboxamides
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB9306578D0 (en) * 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
US5461047A (en) * 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
FR2722788B1 (fr) * 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
RO115159B1 (ro) 1995-01-11 1999-11-30 Samjin Pharmaceutical Co., Ltd Derivaţi de piperazină şi compoziţii farmaceutice care îi conţin
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
CN1152015C (zh) * 1996-06-29 2004-06-02 三进制药株式会社 新哌嗪衍生物及其制造方法
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.
WO1999007672A1 (en) 1997-08-05 1999-02-18 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
WO1999051582A1 (en) * 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
EP1075469B1 (de) 1999-03-03 2004-05-26 Samjin Pharmaceutical Co., Ltd. Piperazinderivate und verfahren zu ihrer herstellung
US6109269A (en) * 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
AU2001280599A1 (en) 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
EP1303483B1 (de) * 2000-08-21 2008-04-23 Pacific Corporation Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
EP1311478B1 (de) * 2000-08-21 2006-06-07 Pacific Corporation Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
MY138086A (en) 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
CN1627944A (zh) 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
JP4326468B2 (ja) * 2002-06-24 2009-09-09 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なインドール誘導体
DK1556354T3 (da) 2002-06-28 2008-06-02 Euro Celtique Sa Terapeutiske piperazinderivater, der er egnede til behandling af smerter
WO2004018479A1 (en) * 2002-08-21 2004-03-04 Astrazeneca Ab Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same

Also Published As

Publication number Publication date
JP2005535731A (ja) 2005-11-24
RS114804A (sr) 2006-12-15
US7279493B2 (en) 2007-10-09
PT1556354E (pt) 2008-04-17
JP4621502B2 (ja) 2011-01-26
DE60318875T2 (de) 2009-01-15
US20110281885A1 (en) 2011-11-17
US7799786B2 (en) 2010-09-21
NO20050371L (no) 2005-03-17
NZ537292A (en) 2006-08-31
CN1678585A (zh) 2005-10-05
US20080153835A1 (en) 2008-06-26
IL165862A0 (en) 2006-01-15
US20040106625A1 (en) 2004-06-03
CY1107411T1 (el) 2012-12-19
BR0312322A (pt) 2005-04-12
DK1556354T3 (da) 2008-06-02
MXPA04012748A (es) 2005-08-15
EP1556354B1 (de) 2008-01-23
HK1082730A1 (en) 2006-06-16
DE60318875D1 (de) 2008-03-13
EA200500114A1 (ru) 2005-06-30
AU2003247829A1 (en) 2004-01-19
WO2004002983A2 (en) 2004-01-08
CN100457735C (zh) 2009-02-04
CA2491079A1 (en) 2004-01-08
CA2491079C (en) 2011-10-04
WO2004002983A3 (en) 2004-03-18
EP1556354A2 (de) 2005-07-27
ES2300613T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
CY1107411T1 (el) Θεραπευτικα παραγωγα πιπεραζινης χρησιμα για την αγωγη του πονου
CY1110004T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του αλγους
ATE465993T1 (de) 2-piperazinpyridine für die schmerzbehandlung
CY1109056T1 (el) Παραγωγα 2-πυριδιν αλκυνιου χρησιμα για την αγωγη του πονου
EA200600077A1 (ru) Гетероарил-тетрагидропиперидильные производные для лечения или профилактики боли
TW200508216A (en) Therapeutic agents useful for treating pain
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
DE602004020994D1 (de) Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
NO20053582L (no) Benzoazolylpiperazinderivater som har VRI- antagonistaktivitet.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556354

Country of ref document: EP